{"id":478200,"date":"2021-04-19T09:40:10","date_gmt":"2021-04-19T13:40:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-immunovant-inc\/"},"modified":"2021-04-19T09:40:10","modified_gmt":"2021-04-19T13:40:10","slug":"april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-immunovant-inc","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-immunovant-inc\/","title":{"rendered":"APRIL 20, 2021, IMVT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a  Securities Class Action Lawsuit Against Immunovant, Inc."},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">NEW YORK<\/span>, <span class=\"xn-chron\">April 19, 2021<\/span> \/PRNewswire\/ &#8212; Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Immunovant, Inc. (&#8220;Immunovant&#8221; or the &#8220;Company&#8221;) (NASDAQ: IMVT) from <span class=\"xn-chron\">October 2, 2019<\/span> through\u00a0 <span class=\"xn-chron\">February 1, 2021<\/span> (the &#8220;Class Period&#8221;). The lawsuit filed in <span class=\"xn-location\">the United States<\/span> District Court for the Eastern District of <span class=\"xn-location\">New York<\/span> alleges violations of the Securities Exchange Act of 1934.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/616919\/Bernstein_Liebhard_LLP_Logo.html\" target=\"_blank\" rel=\"nofollow noopener\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/616919\/Bernstein_Liebhard_LLP_Logo.jpg\" title=\"Bernstein Liebhard LLP.  (PRNewsFoto\/Bernstein Liebhard LLP) (PRNewsfoto\/Bernstein Liebhard LLP)\" alt=\"Bernstein Liebhard LLP.  (PRNewsFoto\/Bernstein Liebhard LLP) (PRNewsfoto\/Bernstein Liebhard LLP)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>If you\u00a0<b>purchased Immunovant securities, and\/or would like to discuss your legal rights and options<\/b>\u00a0please visit\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3129761-1&amp;h=2465012554&amp;u=https%3A%2F%2Fwww.bernlieb.com%2Fcases%2Fimmunovantinc-imvt-shareholder-class-action-lawsuit-stock-fraud-365%2Fapply%2F&amp;a=Immunovant+Shareholder+Class+Action+Lawsuit\" rel=\"nofollow noopener\">Immunovant Shareholder Class Action Lawsuit<\/a>\u00a0or contact\u00a0<a target=\"_blank\" href=\"mailto:MGuarnero@bernlieb.com\" rel=\"nofollow noopener\"><span class=\"xn-person\">Matthew E. Guarnero<\/span><\/a>\u00a0toll free at\u00a0<b>(877) 779-1414<\/b>\u00a0or\u00a0<a target=\"_blank\" href=\"mailto:MGuarnero@bernlieb.com\" rel=\"nofollow noopener\">MGuarnero@bernlieb.com<\/a>.<\/p>\n<p>The complaint alleges that the Defendants made false and\/or misleading statements and\/or failed to disclose that: (i) HSAC had performed inadequate due diligence into Legacy Immunovant prior to the Merger, and\/or ignored or failed to disclose safety issues associated with IMVT-1401; (ii) IMVT-1401 was less safe than the Company had led investors to believe, particularly with respect to treating TED and WAIHA; (iii) the foregoing foreseeably diminished IMVT-1401&#8217;s prospects for regulatory approval, commercial viability, and profitability; and (iv) as a result, the Company&#8217;s public statements were materially false and misleading at all relevant times.<\/p>\n<p>On <span class=\"xn-chron\">February 2, 2021<\/span>, Immunovant issued a press release &#8220;announc[ing] a voluntary pause of dosing in its ongoing clinical trials for IMVT-1401.&#8221; Immunovant disclosed that it &#8220;has become aware of a physiological signal consisting of elevated total cholesterol and LDL [low-density lipoproteins] levels in IMVT-1401-treated patients&#8221; and &#8220;[o]ut of an abundance of caution, the Company has decided to voluntarily pause dosing in ongoing clinical studies in both TED and in [WAIHA], in order to inform patients, investigators, and regulators as well as to modify the monitoring program.&#8221;<\/p>\n<p>On this news, Immunovant&#8217;s stock price fell <span class=\"xn-money\">$18.22<\/span> per share, or 42.08%, to close at <span class=\"xn-money\">$25.08<\/span> per share on <span class=\"xn-chron\">February 2, 2021<\/span>.<\/p>\n<p>A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than <span class=\"xn-chron\">April 20, 2021<\/span>. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn&#8217;t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.<\/p>\n<p>If you\u00a0<b>purchased Immunovant securities, and\/or would like to discuss your legal rights and options<\/b>\u00a0please visit\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3129761-1&amp;h=189893415&amp;u=https%3A%2F%2Fwww.bernlieb.com%2Fcases%2Fimmunovantinc-imvt-shareholder-class-action-lawsuit-stock-fraud-365%2Fapply%2F&amp;a=https%3A%2F%2Fwww.bernlieb.com%2Fcases%2Fimmunovantinc-imvt-shareholder-class-action-lawsuit-stock-fraud-365%2Fapply%2F\" rel=\"nofollow noopener\">https:\/\/www.bernlieb.com\/cases\/immunovantinc-imvt-shareholder-class-action-lawsuit-stock-fraud-365\/apply\/<\/a> or contact\u00a0<a target=\"_blank\" href=\"mailto:MGuarnero@bernlieb.com\" rel=\"nofollow noopener\"><span class=\"xn-person\">Matthew E. Guarnero<\/span><\/a>\u00a0toll free at\u00a0<b>(877) 779-1414<\/b>\u00a0or\u00a0<a target=\"_blank\" href=\"mailto:MGuarnero@bernlieb.com\" rel=\"nofollow noopener\">MGuarnero@bernlieb.com<\/a><\/p>\n<p>Since 1993, Bernstein Liebhard LLP has recovered over <span class=\"xn-money\">$3.5 billion<\/span> for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal&#8217;s &#8220;Plaintiffs&#8217; Hot List&#8221; thirteen times and listed in The Legal 500 for ten consecutive years.<\/p>\n<p>ATTORNEY ADVERTISING. \u00a9 2021 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, <span class=\"xn-location\">New York, New York<\/span> 10016, (212) 779-1414. The lawyer responsible for this advertisement in the <span class=\"xn-location\">State of Connecticut<\/span> is Michael S. Bigin. Prior results do not guarantee or predict a similar outcome with respect to any future matter.<\/p>\n<p>Contact Information<\/p>\n<p>\n        <span class=\"xn-person\">Matthew E. Guarnero<\/span><br \/>\n        <br \/>Bernstein Liebhard LLP<br \/><a href=\"https:\/\/www.bernlieb.com\" rel=\"nofollow\">https:\/\/www.bernlieb.com<\/a><br \/>(877) 779-1414<br \/><a target=\"_blank\" href=\"mailto:MGuarnero@bernlieb.com\" rel=\"nofollow noopener\">MGuarnero@bernlieb.com<\/a><\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=DC43321&amp;sd=2021-04-19\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a--securities-class-action-lawsuit-against-immunovant-inc-301269657.html\">http:\/\/www.prnewswire.com\/news-releases\/april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a&#8211;securities-class-action-lawsuit-against-immunovant-inc-301269657.html<\/a><\/p>\n<p>SOURCE  Bernstein Liebhard LLP<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=DC43321&amp;Transmission_Id=202104190937PR_NEWS_USPR_____DC43321&amp;DateId=20210419\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire NEW YORK, April 19, 2021 \/PRNewswire\/ &#8212; Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Immunovant, Inc. (&#8220;Immunovant&#8221; or the &#8220;Company&#8221;) (NASDAQ: IMVT) from October 2, 2019 through\u00a0 February 1, 2021 (the &#8220;Class Period&#8221;). The lawsuit filed in the United States District Court for the Eastern District of New York alleges violations of the Securities Exchange Act of 1934. If you\u00a0purchased Immunovant securities, and\/or would like to discuss your legal rights and options\u00a0please visit\u00a0Immunovant Shareholder Class Action Lawsuit\u00a0or contact\u00a0Matthew E. Guarnero\u00a0toll free at\u00a0(877) 779-1414\u00a0or\u00a0MGuarnero@bernlieb.com. The &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-immunovant-inc\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;APRIL 20, 2021, IMVT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a  Securities Class Action Lawsuit Against Immunovant, Inc.&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-478200","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>APRIL 20, 2021, IMVT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Immunovant, Inc. - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-immunovant-inc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"APRIL 20, 2021, IMVT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Immunovant, Inc. - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK, April 19, 2021 \/PRNewswire\/ &#8212; Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Immunovant, Inc. (&#8220;Immunovant&#8221; or the &#8220;Company&#8221;) (NASDAQ: IMVT) from October 2, 2019 through\u00a0 February 1, 2021 (the &#8220;Class Period&#8221;). The lawsuit filed in the United States District Court for the Eastern District of New York alleges violations of the Securities Exchange Act of 1934. If you\u00a0purchased Immunovant securities, and\/or would like to discuss your legal rights and options\u00a0please visit\u00a0Immunovant Shareholder Class Action Lawsuit\u00a0or contact\u00a0Matthew E. Guarnero\u00a0toll free at\u00a0(877) 779-1414\u00a0or\u00a0MGuarnero@bernlieb.com. The &hellip; Continue reading &quot;APRIL 20, 2021, IMVT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Immunovant, Inc.&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-immunovant-inc\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-19T13:40:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/616919\/Bernstein_Liebhard_LLP_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-immunovant-inc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-immunovant-inc\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"APRIL 20, 2021, IMVT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Immunovant, Inc.\",\"datePublished\":\"2021-04-19T13:40:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-immunovant-inc\\\/\"},\"wordCount\":635,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-immunovant-inc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/616919\\\/Bernstein_Liebhard_LLP_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-immunovant-inc\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-immunovant-inc\\\/\",\"name\":\"APRIL 20, 2021, IMVT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Immunovant, Inc. - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-immunovant-inc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-immunovant-inc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/616919\\\/Bernstein_Liebhard_LLP_Logo.jpg\",\"datePublished\":\"2021-04-19T13:40:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-immunovant-inc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-immunovant-inc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-immunovant-inc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/616919\\\/Bernstein_Liebhard_LLP_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/616919\\\/Bernstein_Liebhard_LLP_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-immunovant-inc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"APRIL 20, 2021, IMVT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Immunovant, Inc.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"APRIL 20, 2021, IMVT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Immunovant, Inc. - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-immunovant-inc\/","og_locale":"en_US","og_type":"article","og_title":"APRIL 20, 2021, IMVT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Immunovant, Inc. - Market Newsdesk","og_description":"PR Newswire NEW YORK, April 19, 2021 \/PRNewswire\/ &#8212; Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Immunovant, Inc. (&#8220;Immunovant&#8221; or the &#8220;Company&#8221;) (NASDAQ: IMVT) from October 2, 2019 through\u00a0 February 1, 2021 (the &#8220;Class Period&#8221;). The lawsuit filed in the United States District Court for the Eastern District of New York alleges violations of the Securities Exchange Act of 1934. If you\u00a0purchased Immunovant securities, and\/or would like to discuss your legal rights and options\u00a0please visit\u00a0Immunovant Shareholder Class Action Lawsuit\u00a0or contact\u00a0Matthew E. Guarnero\u00a0toll free at\u00a0(877) 779-1414\u00a0or\u00a0MGuarnero@bernlieb.com. The &hellip; Continue reading \"APRIL 20, 2021, IMVT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Immunovant, Inc.\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-immunovant-inc\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-19T13:40:10+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/616919\/Bernstein_Liebhard_LLP_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-immunovant-inc\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-immunovant-inc\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"APRIL 20, 2021, IMVT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Immunovant, Inc.","datePublished":"2021-04-19T13:40:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-immunovant-inc\/"},"wordCount":635,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-immunovant-inc\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/616919\/Bernstein_Liebhard_LLP_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-immunovant-inc\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-immunovant-inc\/","name":"APRIL 20, 2021, IMVT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Immunovant, Inc. - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-immunovant-inc\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-immunovant-inc\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/616919\/Bernstein_Liebhard_LLP_Logo.jpg","datePublished":"2021-04-19T13:40:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-immunovant-inc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-immunovant-inc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-immunovant-inc\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/616919\/Bernstein_Liebhard_LLP_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/616919\/Bernstein_Liebhard_LLP_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/april-20-2021-imvt-filing-deadline-bernstein-liebhard-llp-reminds-investors-of-the-deadline-to-file-a-lead-plaintiff-motion-in-a-securities-class-action-lawsuit-against-immunovant-inc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"APRIL 20, 2021, IMVT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Immunovant, Inc."}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/478200","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=478200"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/478200\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=478200"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=478200"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=478200"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}